Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel

Jefferies raised its price target on Aegerion Pharmaceuticals (NASDAQ: AEGR) from $20 to $22 after FDA panel backing.

"FDA's panel voted 13-2 for recommending approval of lomitapide. Focus now is on the # of eligible patient population & commercial opportunity. Panel discussion did not clearly define # of eligible patients for lomitapide; it remains to be seen what the FDA label says. It would likely be somewhere between 300-3000 patients (pricing likely depends on market size). AEGR to host an investor event on October 23 in New York."

For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.

Shares of Aegerion Pharmaceuticals closed at $19.15 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
• Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities